Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors
Baseline PROs, including dyspnea and physical functioning, have significant prognostic value for survival for patients with advanced non-small cell lung cancer.
Authors
- Eric Yan (ORCID: https://orcid.org/0000-0001-7390-0403)
- Miranda Gogishvili (ORCID: https://orcid.org/0000-0002-5143-6379)
- Mahmut Gümüş (ORCID: https://orcid.org/0009-0001-7894-2319)
- David R. Gandara (ORCID: https://orcid.org/0000-0003-1784-048X)
- Giuseppe Gullo (ORCID: https://orcid.org/0000-0003-4269-4269)
- Tamta Makharadze
- Petra Rietschel
- Ruben G.W. Quek (ORCID: https://orcid.org/0000-0001-9602-3239)
- Ahmet Sezer (ORCID: https://orcid.org/0009-0005-0183-5573)
- Cong Zhu (ORCID: https://orcid.org/0009-0000-6077-4647)
Institutions
- Regeneron (United States) (US)
- Başkent University (TR)
- Batumi State Maritime Academy (GE)
- University of California Davis Medical Center (US)
- Istanbul Medeniyet University (TR)
- Tbilisi State Medical University (GE)
- Cytel (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1640595
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Sanofi
- Regeneron Pharmaceuticals